key: cord-0930142-m804e1ju
authors: Luo, Xia; Liao, Qing; Shen, Ying; Li, Huijun; Cheng, Liming
title: Vitamin D Deficiency Is Inversely Associated with COVID-19 Incidence and Disease Severity in Chinese People
date: 2020-11-13
journal: J Nutr
DOI: 10.1093/jn/nxaa332
sha: b6a18695508d0b8478d81f13fc78a1938bf32a00
doc_id: 930142
cord_uid: m804e1ju

BACKGROUND: Vitamin D might have beneficial potential in influencing the natural history of the coronavirus disease 2019 (COVID-19) due to its immunomodulatory and anti-inflammatory properties. OBJECTIVE: The aim was to investigate whether vitamin D deficiency is associated with COVID-19 incidence and disease severity in Chinese people. METHODS: In a cross-sectional study we retrospectively analyzed 335 COVID-19 patients (median: 56.0; IQR: 43.0–64.0 y) who were admitted to the Wuhan Tongji Hospital between 27 February and 21 March 2020. We also included an age- and sex-matched population of 560 individuals (median: 55; IQR: 49.0–60.0 y) who underwent the physical examination program. Their serum 25-hydroxyvitamin D [25(OH)D] concentrations were measured during the same period from 2018–2019. Serum 25(OH)D concentrations were measured for all COVID-19 patients on admission. Severity of COVID-19 was determined based on the level of respiratory involvement. A general linear model with adjustment for covariates was used to compare 25(OH)D concentrations between the COVID-19 and 2018–2019 control groups. Adjusted ORs with 95% CIs for associations between vitamin D status and COVID-19 severity were estimated via multivariable logistic regression. RESULTS: In the general linear model adjusted for age, sex, comorbidities, and BMI, serum 25(OH)D concentrations were significantly lower among COVID-19 patients than the 2018–2019 controls [ln transformed values of 3.32 ± 0.04 vs. 3.46 ± 0.022 ln (nmol/L), P = 0.014]. Multivariable logistic regression showed that male sex (OR: 2.26; 95% CI: 1.06, 4.82), advanced age (≥65 y) (OR: 4.93; 95% CI: 1.44, 16.9), and vitamin D deficiency (<30 nmol/L) (OR: 2.72; 95% CI: 1.23, 6.01) were significantly associated with COVID-19 severity (all P < 0.05). CONCLUSIONS: These findings suggested that vitamin D deficiency impacts COVID-19 hospitalization and severity in the Chinese population.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of coronavirus disease 2019 . Infected persons display varied symptoms ranging from mild to severe illness, even death. Noticeably, the elderly, men, African Americans, Latinos, and patients with underlying diseases seem to be more susceptible to COVID-19 and are disproportionately affected by severe COVID-19 (1, 2) . To date, the mechanisms underlying this variability are still being elucidated.

Vitamin D is a pluripotent hormone that regulates cellular functions throughout the body. Generally, vitamin D deficiency is more prevalent among people with poor health status, the elderly, and ethnic groups with darker skin (3, 4) . Vitamin D deficiency has been recognized as a pandemic, affecting almost 1 billion people worldwide (5) . These 2 pandemics may be interrelated because they share some common epidemiological characteristics and risk factors (6) . Over the last decade, vitamin D deficiency has been associated with infections and poor outcomes of several common viral infections, such as influenza, HIV type 1, and hepatitis (7) (8) (9) . Science et al. (10) described an inverse relation between serum vitamin D C The Author(s) 2020. Published by Oxford University Press on behalf of the American Society for Nutrition. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com Manuscript received August 13, 2020. Initial review completed August 20, 2020. Revision accepted October 5, 2020. First published online 0, 2020; doi: https://doi.org/10.1093/jn/nxaa332. 1 concentrations and viral respiratory tract infections (RTIs) in a prospective cohort study. The authors observed that serum vitamin D concentrations <75 nmol/L increased the risk of viral RTI by 50% and concentrations <50 nmol/L increased the risk by 70% in 743 children from Canadian Hutterite communities. Similarly, data from meta-analysis of 25 eligible randomized controlled trials from 14 different countries (total 11,321 participants) suggested that vitamin D supplementation reduced the risk of RTIs (OR: 0.88; 95% CI: 0.81, 0.96) and patients with deficient vitamin D experienced the most benefit (OR: 0.30; 95% CI: 0.17, 0.53) (11) . Another long-term prospective cohort study in 426 patients with chronic hepatitis B demonstrated that vitamin D deficiency was independently associated with adverse clinical outcomes (including cirrhotic complications, hepatocellular carcinoma, and/or death) (12) . Vitamin D is anti-inflammatory; it modulates the immune system and is an inhibitor of the renin angiotensin system (RAS). Therefore, it could contribute to resistance against COVID-19 incidence or progression. However, this hypothesis still needs to be tested.

Currently, vitamin D deficiency and COVID-19 are global public health concerns and many studies have investigated the possible relation between these pandemics. A study from Switzerland revealed that vitamin D concentrations were significantly lower in patients with COVID-19 than in those without the disease (13) . Many other studies have also indicated the correlation between vitamin D deficiency and COVID-19 infection, suggesting that vitamin D supplementation could reduce the risk of disease (14) (15) (16) . However, the analyses of UK Biobank data neither supported this potential correlation nor indicated if vitamin D concentrations could explain the differences between ethnic groups regarding the incidence of COVID-19 (17) . Thus, the association between vitamin D status and COVID-19 incidence is controversial. Here, we aimed to explore the association of the serum vitamin D status with COVID-19 incidence and severity in a Chinese population.

This retrospective cross-sectional study was conducted in Tongji Hospital of the Huazhong University of Science and Technology (Wuhan, China). We enrolled 335 consecutive patients with COVID-19 who were admitted to the hospital between 27 February and 21 March 2020. Data regarding demographic characteristics, treatment, ventilation condition, and outcome were retrospectively reviewed from electronic medical records. The follow-up period was extended to 2 May 2020. Six patients eventually died, and the remaining 329 patients survived and were discharged. Meanwhile, we reviewed 22,387 vitamin D measurements from the physical examination program in 2018-2019. The serum vitamin D status of the individuals in this program was influenced by sex, age, and sampling season (Supplemental 

Patients with COVID-19 tested positive for SARS-CoV-2 infection as per nucleic acid tests of nasopharyngeal or oropharyngeal specimens. According to the diagnosis and treatment protocol for novel coronavirus pneumonia (version 7) released by the National Health Commission and State Administration of Traditional Chinese Medicine (18), the COVID-19 patients were classified into 4 levels based on the severity of illness, as follows-1) mild: mild symptoms with no signs of pneumonia on imaging; 2) moderate: fever, respiratory symptoms with radiological evidence of pneumonia; 3) severe [i.e., meeting any of the following: respiratory distress, respiratory rate ≥30 breaths/min, hypoxemia, oxygen saturation (SpO 2 ) ≤93% (at rest), or lung infiltrates of >50% within 24-48 h]; and 4) critical (i.e., meeting any of the following criteria: respiratory failure requiring mechanical ventilation, shock, or multiple organ dysfunction requiring intensive care unit monitoring and treatment). In this study, mild and moderate cases were classified into the nonsevere group, while severe and critical cases were classified into the severe group. Nonsevere patients whose symptoms became progressively severe during hospitalization were defined as severe cases. With regard to vitamin D concentrations, patients were categorized into vitamin D-deficient (<30 nmol/L) and non-vitamin D-deficient (≥30 nmol/L) groups. BMI was calculated as weight (kilograms) divided by height (meters) squared (kg/m 2 ). The estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation developed in 2009 (19) .

Blood samples were obtained from each COVID-19 patient upon admission. For the purpose of this study, serum 25-hydroxyvitamin D [25(OH)D] concentration, which represents the major circulating form of vitamin D, was determined using chemiluminescence immunoassay (DiaSorin, Inc.). Routine tests for COVID-19 to detect plasma concentrations of high-sensitivity C-reactive protein, calcium, phosphate, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and lactate dehydrogenase were measured using the Cobas 8000 system (ISE module, c701, c701, c701, and c502; Roche Diagnostics) and original reagents. Serum procalcitonin and IL-6 concentrations were evaluated with the Cobas e602 immunoassay analyzer using original reagents (Roche Diagnostics). D-dimer was assessed with a STA-R MAX coagulation analyzer (Diagnostica Stago) using commercially available kits. Complete blood count was conducted using the Sysmex XE-2100 hematology analyzer (Sysmex). All tests were performed in the Department of Laboratory Medicine, Tongji Hospital.

Statistical analysis was performed using GraphPad Prism (version 5.0; GraphPad Software, Inc.) and SPSS (version 20.0; IBM, Inc.). Data normality was analyzed using the Kolmogorov-Smirnov test. Normally distributed data were compared using the unpaired t test and expressed as means ± SDs. Non-normally distributed data are expressed as medians and IQRs. Between-group comparisons were assessed using the Mann-Whitney U test, while between-group comparisons were analyzed using the Kruskal-Wallis test and Dunn's multiple-comparison test. Pearson's chi-square test or Fisher's exact test was performed to analyze the categorical data. A general linear model with adjustment for covariates was used to compare the serum 25(OH)D concentrations between COVID-19 patients and the 2018-2019 controls. A multivariable logistic regression model adjusted for confounding factors was used to estimate the ORs, 95% CIs, and P values for associations between serum 25(OH)D concentrations and COVID-19 severity. Multiple linear regression was used to determine the association between serum 25(OH)D and ln-transformed hospital stay, adjusted for age, sex, comorbidities, smoking status, and BMI. P values were 2-tailed, and P < 0.05 was considered statistically significant.

A total of 335 COVID-19 patients and 560 controls from 2018-2019 were included in this study. Table 1 (Figure 1) . Back-transformed means were 27.7 nmol/L and 31.8 nmol/L, respectively.

In the COVID-19 group, 261 (77.9%) patients were categorized as nonsevere and 74 (22.1%) were categorized as severe ( Table 1) Table 1 ; P = 0.0001). During the follow-up period, 329 COVID-19 patients survived and were discharged and the remaining 6 died. In the linear regression Table 2) .

Six of the 74 severe COVID-19 patients (8.11%), of whom 5 were males, eventually died. The remaining 68 patients survived and were discharged ( 

The COVID-19 outbreak has become a global threat. Public health measures to reduce the risk of infection, severity, and death are desperately needed. Currently, there is no strong evidence from the intervention trials to conclusively prove that vitamin D beneficially affects COVID-19 outcomes. However, a few retrospective observational studies evaluated the relation between vitamin D status and incidence of COVID-19 (17, 20, 21) . Our study revealed that 25(OH)D concentrations on admission were significantly lower in COVID-19 patients than in the 2018-2019 controls, even after adjusting for comorbidities, BMI, age, and sex. An Israeli population study with 7807 participants demonstrated that vitamin D concentrations were significantly lower among the COVID-19positive individuals than COVID-19-negative individuals (20) . Similarly, a retrospective cohort study from the University of Chicago Medicinein the United States included 499 patients who underwent vitamin D measurement and treatment within 1 y before they were tested for SARS-CoV-2 (21). The study indicated that patients with vitamin D deficiency, who were not sufficiently treated, were at an increased relative risk of COVID-19 infection compared with patients with likely sufficient vitamin D concentrations. The vitamin D measurements in these 2 studies were not performed while SARS-CoV-2 tests were carried out. Thus, the actual vitamin D status may not have been reflected. Furthermore, a recent study from the United Kingdom, which recruited 348,598 Biobank participants, found that the vitamin D concentration was associated with COVID-19 infection in a univariate analysis, but not after adjustment for confounders, including ethnicity, age, sex, smoking status, health rating, household income, and BMI, to name a few (17) . However, the baseline vitamin D concentration and health status in the study were obtained 10 y prior, which could have resulted in a time-lag bias. In our study, vitamin D deficiency was more common in COVID-19 patients than in 2018-2019 controls, indicating that vitamin D deficiency could be a risk factor for SARS-CoV-2 infection. However, this cross-sectional analysis does not allow us to draw conclusions regarding causality, and more research is needed. Overall, evidence suggests that vitamin D could be an etiological factor in COVID-19 infection. Our data revealed significantly lower serum 25(OH)D concentrations in severe COVID-19 patients than in nonsevere patients. We observed that vitamin D deficiency was associated with COVID-19 severity, after adjusting for several potential confounders, such as age, sex, comorbidities, BMI, and smoking status. While stratifying the severe COVID-19 patients by outcomes, it was found that 25(OH)D concentrations in the death group were lower (but not significant) than that in the discharged group (18.7 nmol/L vs 23.2 nmol/L). This was likely due to the small number of patients in the death group. Recently, a single-center, retrospective, and observational study investigated the possible associations of vitamin D status with disease severity and survival (22) . The authors examined 185 COVID-19 patients, of whom 28 patients had invasive mechanical ventilation and/or died. This study showed that vitamin D deficiency (<30 nmol/L) was associated with higher risk of invasive mechanical ventilation and/or death [HR (95% CI): 6.12 (2.79, 13 .42) and 14.73 (4.16, 52.19) ; P < 0.001, respectively]. It is noteworthy that the disease severity criteria in this study were different from ours as mentioned above. Altogether, vitamin D deficiency could act as an important risk factor for COVID-19 severity.

The role of vitamin D in barrier function and innate immunity could partially explain the relation of vitamin D deficiency with COVID-19 incidence and disease severity. Vitamin D promotes barrier integrity by upregulating a complex set of proteins (23) and inducing the expression of defense peptides, such as cathelicidin and β-defensins (24) ; both of these functions protect the host from pathogen invasion.

Recently, the RAS has been suggested as a potential mechanism underlying the association between vitamin D and COVID-19 (25) . SARS-CoV-2 infection can enhance angiotensinconverting enzyme (ACE)/angiotensin II expression and reduce ACE2/angiotensin-(1-7) concentrations (25) . This is conducive for COVID-19 pathogenesis and subsequent disease severity and mortality. However, vitamin D negatively regulates the RAS by inhibiting renin, ACE, and angiotensin II and activating the ACE2/angiotensin-(1-7) axis, thereby exerting protective effects against COVID-19 (16, 26) . Uncontrolled inflammation and cytokine release also play critical roles in COVID-19 pathogenesis and clinical manifestations. Increasing evidence indicates that vitamin D can suppress the expression of proinflammatory cytokines, such as IL-6, TNF-α, IFN-γ , IL-1β, IL-8, and IFN-γ , in immune cells (27) . It induces this effect by increasing intracellular glutathione concentrations and suppressing excessive reactive oxygen species, NF-κB, and p38 mitogen-activated protein kinase expression. Furthermore, vitamin D exerts anti-inflammatory effects by promoting anti-inflammatory cytokine generation, such as transforming growth factor-β and IL-10 (27, 28) . Therefore, vitamin D may reduce cytokine storm syndrome in COVID-19 patients and prevent multiple organ damage. Additionally, thrombotic or thromboembolic events are common in patients with severe COVID-19. The antithrombotic effects of vitamin D in other conditions have been well documented (29, 30) and may also apply to COVID-19. Taken together, vitamin D may play an important role in reducing the risk of COVID-19 development, progression, and severity. Our study has several strengths. Most importantly, this is a real-world study investigating, for the first time, the vitamin D status of COVID-19 patients in a Chinese population. Additionally, sample collections from COVID-19 patients for serum 25(OH)D were completed within ∼1 mo for reducing seasonal variation in vitamin D status. However, the study also had some limitations. First, the cross-sectional study design may be a major limitation. Although vitamin D deficiency was associated with COVID-19 incidence and disease severity, we could not establish the causality. Better-designed clinical trials are warranted in the future. Second, we could not obtain a sufficient number of vitamin D measurements from populationwide tests during the study period (2020) due to the COVID-19 outbreak. Thus, we selected the 2018-2019 cohort as representative of vitamin D status of the general public. Third, information on smoking status was not available for the 2018-2019 controls. While we assessed the potential impact of vitamin D deficiency on COVID-19 incidence, this risk factor was not controlled for.

In conclusion, our study showed that individuals with vitamin D deficiency were more common among patients with COVID-19 infection and severe illness. Interventional trials would be helpful in clarifying the role of vitamin D in COVID-19 infection and disease severity.

Clinical course and mortality risk of severe COVID-19

COVID-19 and racial/ethnic disparities

Vitamin D deficiency

Vitamin D and chronic diseases

Vitamin D: the "sunshine" vitamin

Vitamin D deficiency and COVID-19 5

Scientific strabismus" or two related pandemics: coronavirus disease and vitamin D deficiency

Vitamin D and the anti-viral state

An update on the association of vitamin D deficiency with common infectious diseases

The interplay between vitamin D and viral infections

Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B

25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2

Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees north supports vitamin D as a factor determining severity

Vitamin D can prevent COVID-19 infection-induced multiple organ damage

National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)

A new equation to estimate glomerular filtration rate

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

Association of vitamin D deficiency and treatment with COVID-19 incidence. medRxiv

Vitamin D deficiency and outcome of COVID-19 patients

Vitamin D, vitamin D receptor, and tissue barriers

A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency

COVID-19-does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE 2 attack?

Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the reninangiotensin system

The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging

Anti-inflammatory effects of vitamin D on human immune cells in the context of bacterial infection

The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome

Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy

We thank the Department of Laboratory Medicine, Tongji Hospital, for providing instruments and reagents for sample testing. The authors' responsibilities were as follows-XL and LC: designed the research and drafted the manuscript; QL, YS, and HL: were responsible for specimen collection and measurement and conducted the statistical analysis; LC: had primary responsibility for final content; and all authors: were involved in critical revisions and read and approved the final manuscript.